That makes the most sense. Tumor heterogeneity is one of the big issues with GBM. New tumor has new antigens, thus it needs new DCVAX formula from the recurred lysate.
Since picking up as much as tumor antigens is so important, I would suggest NWBO develops better methods for DCVax- Direct to pick up more tumor antigens when dendritic cells injected to the solid tumors.
Looks like the company already knew how to prime the dendritic cells but using needles to deliver the cells to the tumors directly on DcVax- Direct. I wonder if that needles are effective for that purpose? Equipment manufacturers can help develop creative devices that work much better than current method. That device can simulate how to create tumor lysate inside the body. Imo..
News 
Market Data 
Discover 
